---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-022608"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:50:39.800973+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# RenovoRx reports Q2 2022 net loss of $2.6M; cash $10.8M; Phase 3 interim analysis expected Q4 2022

## Summary
- Net loss of $2.6M for Q2 2022 vs $1.3M in Q2 2021; R&D expense $1.4M vs $0.5M.
- Cash and equivalents and short-term marketable securities of $10.8M as of June 30, 2022.
- Phase 3 TIGeR-PaC first prospective interim analysis expected in Q4 2022.
- Protocol for Phase 2/3 trial in extrahepatic cholangiocarcinoma submitted to FDA; first patient enrollment planned Q4 2022.
- Appointed James Ahlers as CFO and Ron Kocak as VP & Controller in July 2022.

## SEC filing metadata
- accession: 0001493152-22-022608
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315222022608/0001493152-22-022608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315222022608/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-022608
- JSON: https://secwatch.observer/filing/0001493152-22-022608.json
- Plain text: https://secwatch.observer/filing/0001493152-22-022608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.